Identification of pathogenic germline variants in a large Chinese lung cancer cohort by clinical sequencing
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13548 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Zhe Yu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Ningbo NO.2 Hospital, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Germ-Line Mutation, Genetic Predisposition to Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Beijing Medical Public Welfare Foundation, Nanjing City Key Medical Science and Technology Project Plan.
Abstract (Originalsprache)
Genetic factors play significant roles in the tumorigenicity of lung cancer; however, there is lack of systematic and large‐scale characterization of pathogenic germline variants for lung cancer. In this study, germline variants in 146 preselected cancer‐susceptibility genes were detected in 17 904 Chinese lung cancer patients by clinical next‐generation sequencing. Among 17 904 patients, 1738 patients (9.7%) carried 1840 pathogenic/likely pathogenic (P/LP) variants from 87 cancer‐susceptibility genes. SBDS (SBDS ribosome maturation factor) (1.37%), TSHR (thyroid stimulating hormone receptor) (1.20%), BLM (BLM RecQ like helicase) (0.62%), BRCA2 (BRCA2 DNA repair associated) (0.62%), and ATM (ATM serine/threonine kinase) (0.45%) were the top five genes with the highest overall prevalence. The top mutated pathways were all involved in DNA damage repair (DDR). Case–control analysis showed SBDS c.184A>T(p.K62*), TSHR c.1574T>C(p.F525S), BRIP1 (BRCA1 interacting helicase 1) c.1018C>T(p.L340F), and MUTYH (mutY DNA glycosylase) c.55C>T(p.R19*) were significantly associated with increased lung cancer risk ( q value < 0.05). P/LP variants in certain genes were associated with early onset of lung cancer. Our study indicates that Chinese lung cancer patients have a higher prevalence of P/LP variants than previously reported. P/LP variants are distributed in multiple pathways and dominated by DNA damage repair‐associated pathways. The association between identified P/LP variants and lung cancer risk requires further studies for verification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Ningbo NO.2 Hospital, China.
- Department of Cardiovascular and Thoracic Surgery, Nanjing Drum Tower Hospital Affiliated to Nanjing University School of Medicine, China.
- Department of Chemotherapy, Affiliated Hospital of Nantong University, China.
- Nanjing Geneseeq Technology Inc., China.
- School of Public Health, Nanjing Medical University, China.
- Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
ORCID-Profile: Xiaojun Fan, Jiani Yin, Zhengcheng Liu, Fang Liu
Förderung
- The Beijing Medical Public Welfare Foundation
- Nanjing City Key Medical Science and Technology Project Plan
Zitieren
APA
Yu, Z., Zhang, Z., Liu, J., Wu, X., Fan, X., Pang, J., Bao, H., Yin, J., Wu, X., Shao, Y., Liu, Z., & Liu, F. (2024). Identification of pathogenic germline variants in a large Chinese lung cancer cohort by clinical sequencing. Molecular Oncology. https://doi.org/10.1002/1878-0261.13548
Vancouver
Yu Z, Zhang Z, Liu J, Wu X, Fan X, Pang J, et al. Identification of pathogenic germline variants in a large Chinese lung cancer cohort by clinical sequencing. Molecular Oncology. 2024. doi:10.1002/1878-0261.13548
BibTeX
@article{Yu2024,
author = {Yu, Zhe and Zhang, Zirui and Liu, Jun and Wu, Xiaoying and Fan, Xiaojun and Pang, Jiaohui and Bao, Hua and Yin, Jiani and Wu, Xue and Shao, Yang and Liu, Zhengcheng and Liu, Fang},
title = {Identification of pathogenic germline variants in a large Chinese lung cancer cohort by clinical sequencing},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13548}
}
EUVIMED